Monoclonal Antibodies
Anti-FGF23 Rabbit Monoclonal Antibody for WB, IF/ICC, ELISA - Q9GZV9
Item Number : CM0007624
Price varies based on specs and customizations
- Application
- WB, IF/ICC, ELISA
- Cross Reactivity
- Human
- Protein Weight
- 28kDa
Shipping:
Contact us to get shipping details Enjoy On-time Dispatch Guarantee.
Why Choose Us
Easy ordering process, quality products, and dedicated support for your business success.
Core Product Specifications and Parameters
| Parameter | Value |
|---|---|
| Product Name | FGF23 Rabbit mAb |
| Remarks/Alias | ADHR; FGFN; HYPF; HFTC2; HPDR2; PHPTC; FGF23 |
| Species | Human |
| GeneID (human) | 8074 |
| GeneID | 8074 |
| Immunogen | Recombinant fusion protein containing a sequence corresponding to amino acids 25-251 of human FGF23 (NP_065689.1) |
| Source | Rabbit |
| Category | Monoclonal Antibodies |
| Application | WB, IF/ICC, ELISA |
| Cross Reactivity | Human |
| SWISS | Q9GZV9 |
| Protein Weight | 28kDa |
| Shipping | Ice bag |
Biological Background: Fibroblast growth factor 23 Function and Localization
- FGF23 is a critical endocrine regulator of phosphate homeostasis, controlling renal phosphate excretion. Related references: PMID:11062477
- It inhibits renal tubular phosphate transport by downregulating SLC34A1 expression. Related references: PMID:11409890
- The protein also modulates vitamin D metabolism, contributing to systemic mineral balance. Related references: PMID:15040831
- In the presence of α-Klotho, FGF23 up-regulates EGR1 and directly suppresses parathyroid hormone secretion from the parathyroid gland.
- FGF23 negatively regulates osteoblast differentiation and bone matrix mineralization, linking bone remodeling to phosphate handling. Related references: PMID:18282132
- It is predominantly expressed by osteocytes and osteogenic cells in bone and is secreted into the bloodstream.
- Post-translational modifications include glycosylation and phosphorylation, and it possesses a signal peptide and disulfide bonds essential for its structure.
- Mutations in FGF23 cause human diseases such as autosomal dominant hypophosphatemic rickets (ADHR) and hyperphosphatemic familial tumoral calcinosis (HFTC2), reflected in its alternate names.
Experimental Guidance and Technical Tips
- For Western blotting, the predicted molecular weight is approximately 28 kDa; validate the observed band in your sample system and consider using appropriate positive controls.
- In immunofluorescence/immunocytochemistry (IF/ICC), human osteoblast or osteocyte cell lines may serve as suitable positive controls; optimize fixation and permeabilization conditions.
- For ELISA applications, pairing with a suitable detection antibody may be necessary; perform assay optimization according to your protocol.
- Since this monoclonal antibody was raised against a recombinant fragment covering the mature protein, it may detect both full-length and processed forms; confirm specificity in your experimental model.
CamelBio: Your One-Stop Sourcing Bridge
CamelBio provides diagnostic manufacturers and research laboratories with comprehensive access to validated antibodies, including this anti-FGF23 monoclonal antibody, for studying phosphate regulation and bone metabolism. Our portfolio includes optimized monoclonal/polyclonal antibodies, recombinant proteins, and ancillary reagents to support assay development. For rare or specialized targets, we offer custom sourcing and technical consultancy from concept to clinical application.
REQUEST A QUOTE
Our professional team will reply to you within one business day. Please feel free to contact us!